Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia: Letter to Editor

Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia: Letter to Editor

Bibliographic Details
Main Authors:	Sakiyeva Kanshaiym, Gulmira Zhurabekova, Ibrahim A. Abdelazim, Tatyana Starchenko
Format:	Article
Language:	English
Published:	Elsevier 2020-01-01
Series:	Hematology, Transfusion and Cell Therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2531137919300537

Similar Items

Intravenous ferric carboxymaltose for the treatment of iron deﬁciency anemia
by: João Ricardo Friedrisch, et al.
Published: (2015-12-01)

Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia
by: Melvin H. Seid, et al.
Published: (2017-01-01)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anaemia – reply
by: Rodolfo Delfini Cancado, et al.
Published: (2020-01-01)

Effect of intravenous iron sucrose on hemoglobin level, when administered in a standard dose, to anemic pregnant women in rural Northern India
by: Sakiyeva Kanshaiym, et al.
Published: (2019-01-01)

The role of ferric carboxymaltose in the treatment of iron deficiency anemia in patients with gastrointestinal disease
by: Pramoda Koduru, et al.
Published: (2016-01-01)

Safety and Efficacy of Intravenous Ferric Carboxymaltose (750 mg) in the Treatment of Iron Deficiency Anemia: Two Randomized, Controlled Trials
by: Charles F. Barish, et al.
Published: (2012-01-01)

Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose for the ambulatory treatment of severe iron deficiency.
by: Xavier Calvet, et al.
Published: (2012-01-01)

Iron deficiency anemia with menorrhagia: Ferric carboxymaltose a safer alternative to blood transfusion
by: Vineet Mishra, et al.
Published: (2018-01-01)

Assessing the costs and benefits of perioperative iron deficiency anemia management with ferric carboxymaltose in Germany
by: Froessler B, et al.
Published: (2018-04-01)

Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency Anemia
by: Iftikhar Hussain, et al.
Published: (2013-01-01)

Comparison of ferric Carboxymaltose and iron sucrose complex for treatment of iron deficiency anemia in pregnancy- randomised controlled trial
by: Ambily Jose, et al.
Published: (2019-02-01)

Efficacy and cost effectiveness of intravenous ferric carboxymaltose versus iron sucrose in adult patients with iron deficiency anaemia
by: Ahmad Basha, et al.
Published: (2021-01-01)

Efficacy and safety of intravenous ferric carboxymaltose in iron deficiency anemia; Real-life data from Turkey, a single center experience
by: Ali Eser, et al.
Published: (2021-06-01)

Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose
by: Wendy Fang, et al.
Published: (2019-10-01)

Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose
by: Toblli JE, et al.
Published: (2014-12-01)

An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and Finland
by: Pollock RF, et al.
Published: (2021-01-01)

Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anemia: phase IV clinical trials
by: Amreen Naqash, et al.
Published: (2018-01-01)

Successful Procedure in Conservative Management of Interstitial (Cornual) Ectopic Pregnancy
by: Sakiyeva Kanshaiym, et al.
Published: (2019-01-01)

Treatment of anemia in cancer patients undergoing chemotherapy with intravenous ferric carboxymaltose without erythropoiesis-stimulating agents
by: Hikmat Abdel-Razeq, et al.
Published: (2020-09-01)

IV Ferric Carboxymaltose Vs Oral Iron in the Treatment of Post-partum Iron Deficiency Anaemia
by: Sree Chandana Damineni, et al.
Published: (2016-11-01)

Intravenous Iron Carboxymaltose as a Potential Therapeutic in Anemia of Inflammation.
by: Niklas Lofruthe, et al.
Published: (2016-01-01)

Efficacy and safety of ferric carboxymaltose versus ferrous sulfate for iron deficiency anemia during pregnancy: subgroup analysis of Korean women
by: Jae-Yoon Shim, et al.
Published: (2018-08-01)

REGAIN STUDY: Retrospective Study to Assess the Effectiveness, Tolerability, and Safety of Ferric Carboxymaltose in the Management of Iron Deficiency Anemia in Pregnant Women
by: Saleema Wani, et al.
Published: (2019-01-01)

Adverse Reactions of Ferric Carboxymaltose
by: HARISH THANUSUBRAMANIAN, et al.
Published: (2014-10-01)

Delayed Hypersensitivity with Ferric Carboxymaltose
by: Surabhi Sridhara, et al.
Published: (2017-11-01)

Ferric carboxymaltose for the treatment of iron‐deficient heart failure patients: a systematic review and meta‐analysis
by: Muhammad Shahzeb Khan, et al.
Published: (2020-12-01)

Comparative safety of intravenous Ferumoxytol versus Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia: rationale and study design of a randomized double-blind study with a focus on acute hypersensitivity reactions
by: Adkinson NF, et al.
Published: (2017-09-01)

Intravenous ferric carboxymaltose does not provide benefits in reperfused acute myocardial infarction in the rat with normal iron status
by: Aleksandra Paterek, et al.
Published: (2021-09-01)

Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing
by: Matthias Diebold, et al.
Published: (2019-03-01)

Rationale and design of the IRON‐CRT trial: effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapy
by: Pieter Martens, et al.
Published: (2019-12-01)

Efficacy and Tolerability of Intravenous Ferric Carboxymaltose in Patients with Iron Deficiency at a Hospital Outpatient Clinic: A Retrospective Cohort Study of Real-World Clinical Practice
by: António Robalo Nunes, et al.
Published: (2017-01-01)

Rationale and design of the IRON-AF study: a double-blind, randomised, placebo-controlled study to assess the effect of intravenous ferric carboxymaltose in patients with atrial fibrillation and iron deficiency
by: Michael B Stokes, et al.
Published: (2021-08-01)

Cardiovascular, liver, and renal toxicity associated with an intravenous ferric carboxymaltose similar versus the originator compound
by: Toblli JE, et al.
Published: (2017-11-01)

TREATMENT OF ANEMIA AND IMPROVEMENT OF QUALITY OF LIFE AMONG PATIENTS WITH CROHN'S DISEASE: experience using ferric carboxymaltose
by: Carlos Walter SOBRADO, et al.
Published: (2015-12-01)

Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients
by: Jesse M. G. Hofman, et al.
Published: (2018-09-01)

Corrigendum to “Efficacy and Tolerability of Intravenous Ferric Carboxymaltose in Patients with Iron Deficiency at a Hospital Outpatient Clinic: A Retrospective Cohort Study of Real-World Clinical Practice”
by: António Robalo Nunes, et al.
Published: (2019-01-01)

Abdelazim and Sakiyeva endocrinopathy associated with polycystic ovary syndrome: Case reports
by: Ibrahim A Abdelazim, et al.
Published: (2019-01-01)

Hypophoshatemia Incidence in Patients with Chronic Kidney Disease Treated with Intravenous Ferric Carboxymaltose and Factors Related to Hypophosphatemia
by: Abdullah Şumnu, et al.
Published: (2020-09-01)

Efficacy and Safety of Intravenous Ferric Carboxymaltose in Patients with Postoperative Anemia Following Same-Day Bilateral Total Knee Arthroplasty: A Randomized Controlled Trial
by: Man Soo Kim, et al.
Published: (2021-04-01)

Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women--PREFER a randomized, placebo-controlled study.
by: Bernard Favrat, et al.
Published: (2014-01-01)

Cannot write session to /tmp/vufind_sessions/sess_p1hhhnjpu2fm362bkou69tuekt